News
AM-001 Study represents a pivotal milestone in Galmed's transition to Aramchol Meglumine, an improved formulation of its lead compound in advanced clinical development – Aramchol Meglumine ...
(RTTNews) - Galmed Pharmaceuticals (GLMD) announced positive preliminary results from Part 1 of the Ph1 Bioavailability AM-001 Study of Aramchol Meglumine. The company said initial findings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback